Introduction to CJC-1295 for Research Applications
CJC-1295 is a synthetic tetra-substituted peptide analog of growth hormone‑releasing hormone (GHRH) that has garnered interest in biochemical and endocrine research. Its primary molecular design involves four amino acid substitutions within the native GHRH(1‑29) sequence together with a reactive linker group, which allows for site‑specific conjugation to serum albumin in vitro. This structural modification prolongs the experimental half‑life of the peptide under laboratory conditions, making it a valuable tool for long‑duration signaling studies. Researchers commonly employ CJC-1295 to investigate GHRH receptor binding kinetics, intracellular cAMP accumulation, and downstream pulsatile hormone release patterns in isolated pituitary cell models. All investigations are conducted solely in controlled laboratory environments; the product is not intended for any form of human or veterinary application.
The peptide’s use is limited to basic science and early‑stage discovery programs where a stable GHRH receptor agonist is required. Typical experimental endpoints include receptor occupancy assays, transcriptional profiling of somatotrophs, and modulation of insulin‑like growth factor‑1 secretion in established cell lines. By offering a consistent chemical identity and high batch‑to‑batch fidelity, CJC-1295 enables reproducible outcomes across multi‑institutional collaborations. As with all research‑grade peptides, the compound is distributed exclusively to qualified laboratories and must be handled in accordance with institutional safety guidelines.
Quality Assurance in CJC-1295 Supply
Ensuring a reliable 99 percent purity level is fundamental for meaningful research data, and every batch of CJC-1295 from our facility undergoes rigorous analytical characterization before release. Our quality assurance program is built around orthogonal methods that confirm both the quantitative purity and the qualitative identity of the peptide. High‑performance liquid chromatography (HPLC) is the primary tool for purity assessment, while high‑resolution mass spectrometry verifies the expected molecular weight and absence of sequence deletions or side‑product modifications.
A Certificate of Analysis (CoA) accompanies each shipment, detailing the specific lot number, net peptide content, purity percentage determined by HPLC, mass spectrum, and residual solvent profile. This documentation allows researchers to correlate experimental results directly with the physicochemical properties of the peptide they received. In addition to end‑product testing, we employ a system of in‑process controls that monitor critical synthesis and purification steps. These measures collectively guarantee that every gram of CJC-1295 meets the 99 percent specification, thereby supporting the reproducibility that peer‑reviewed journals and institutional review boards expect from commercial peptide sources.
Synthesis and Purification Methods
Manufacture of CJC-1295 begins with solid‑phase peptide synthesis (SPPS) using Fmoc‑protected amino acids. This stepwise assembly on a resin support enables precise control over the linear chain growth, minimizing racemization and deletion sequences. The reactive linker moiety is introduced during solid‑phase construction under optimized coupling conditions, ensuring consistent incorporation. After cleavage from the resin, the crude peptide is precipitated and lyophilized before entering the purification stage.
Reverse‑phase HPLC with a C18 stationary phase serves as the principal purification method. A water‑acetonitrile gradient containing a small percentage of trifluoroacetic acid resolves the target peptide from closely related deletion, truncation, and epimerization impurities. Fractions are collected and analyzed in real time by analytical HPLC, and only those meeting the ≥99 percent purity threshold are pooled. The final solution is then lyophilized under sterile conditions, yielding a white to off‑white powder that retains its stability for extended periods when stored correctly. Lyophilization removes water by sublimation, which prevents chemical degradation and microbial growth without the need for preservatives.
Purity Verification Protocols
Verifying a 99 percent purity claim requires a multi‑technique approach that leaves no ambiguity about the peptide’s identity or cleanliness. Our standard protocol begins with reversed‑phase analytical HPLC monitored by UV absorbance at 214 nm, a wavelength where the peptide bond exhibits strong absorption. The chromatogram is integrated to calculate the relative peak areas of the main product versus all detectable impurities. A single, symmetrical peak representing more than 99 percent of the total area serves as the primary acceptance criterion.
Electrospray ionization mass spectrometry (ESI‑MS) or matrix‑assisted laser desorption/ionization time‑of‑flight (MALDI‑TOF) analysis confirms the molecular mass within ±0.5 Da of the theoretical monoisotopic value. This step detects any covalent modifications, such as oxidation of methionine residues or incomplete deprotection, that might escape HPLC resolution. Complementary analysis for residual organic solvents is performed by gas chromatography according to pharmacopeial guidelines, ensuring that levels of acetonitrile, trifluoroacetic acid, and other processing reagents fall below established safety thresholds for laboratory exposure. Only after these three independent tests are passed does a batch receive its lot number and CoA.
Third-Party Testing and Compliance
To reinforce confidence in our analytical results, we engage ISO‑accredited independent laboratories for periodic blinded verification. These third parties repeat the HPLC purity, mass spectrometry, and residual solvent analyses on randomly selected retention samples, and their reports are archived alongside our internal data. This external oversight provides an objective check on equipment calibration and operator proficiency. Furthermore, our synthesis and quality control procedures follow relevant Good Manufacturing Practice (GMP) principles adapted for research‑grade peptides, including raw material qualification, equipment cleaning validation, and controlled documentation of every production step.
All documentation, from the master batch record to the final CoA and third‑party summary, is available for regulatory review when research programs transition toward later‑stage development. This level of transparency supports the due diligence requirements of pharmaceutical distributors and institutional procurement departments. By maintaining a permanent audit trail, we help customers demonstrate the provenance and purity of the CJC-1295 used in their published studies, which is increasingly requested by journal editors and grant reviewers.
Proper Storage and Handling for Research Use
Maintaining the structural integrity of CJC-1295 during long‑term storage is essential for experimental consistency. Upon receipt, the lyophilized powder should be inspected for cake appearance and immediately transferred to a frost‑free freezer set at −20 °C or colder. Vials must be kept in a sealed container with desiccant to prevent moisture absorption, as even trace amounts of water can initiate deamidation or aggregation over time. Under these conditions, lyophilized CJC-1295 remains chemically stable for the duration stated on the CoA, typically 24 months from the date of manufacture.
For in vitro assays, the peptide is reconstituted in sterile, deionized water or an appropriate buffer (such as phosphate‑buffered saline, pH 7.4) at a concentration suitable for the experimental design, typically 1‑5 mg/mL. Gentle swirling—never vortexing—dissolves the material without foaming or shear‑induced aggregation. The resulting stock solution should be aliquoted into single‑use portions and stored at −20 °C or −80 °C. Repeated freeze‑thaw cycles are detrimental, as they expose the peptide to fluctuating solute concentrations and ice‑crystal interfaces that accelerate degradation. Researchers are advised to thaw each aliquot once, immediately before use, and to discard any unused thawed solution.
Why Choose Our CJC-1295 for Your Research
As a direct manufacturer with dedicated peptide synthesis laboratories, we offer CJC-1295 in quantities ranging from milligrams to multi‑gram bulk orders, all produced to the same 99 percent purity standard. This vertical integration eliminates intermediaries, shortens lead times, and permits real‑time customization of packaging and labeling to suit institutional requirements. We employ a just‑in‑time production model for high‑demand items, which reduces the need for prolonged storage at our facility and ensures that customers receive freshly synthesized material with maximum remaining shelf life.
Price competitiveness is achieved without sacrificing quality. Our process development team continually refines coupling cycles, cleavage conditions, and HPLC gradients to maximize yield per synthesis run, and these efficiencies translate into lower cost per gram for the end user. Large‑scale orders benefit from additional economy while still receiving the full suite of analytical documentation. Every shipment, irrespective of size, is dispatched in temperature‑controlled packaging with data‑logging devices that record the cold chain from our warehouse to the receiving dock. This commitment to cold‑chain integrity is particularly critical for lyophilized peptides, as prolonged ambient exposure during transit can shorten usable life. For international orders, we provide the necessary customs documentation to facilitate smooth clearance, and dedicated customer support representatives track each parcel until delivery confirmation.
Frequently Asked Questions about CJC-1295 Supply
What is the typical lead time for orders?
Standard catalog quantities (5 mg to 100 mg) usually ship within 3‑5 business days after order confirmation. Custom bulk orders may require 2‑4 weeks for synthesis, purification, and quality release. The exact timeline is provided at quotation stage, and we offer expedited synthesis slots for repeat customers with pre‑approved specifications.
How is purity guaranteed for long‑term research projects?
We maintain a retention sample of every batch and perform annual stability‑indicating HPLC and mass spectrometry tests on these samples. If a project spans multiple years, we can reserve a dedicated lot from a single synthesis run, providing an extensive stability dataset that covers the entire project lifetime. Re‑analysis certificates are issued upon request, allowing investigators to confirm that peptide integrity has remained unchanged while in their own laboratory storage.
What documentation accompanies each shipment?
Inside every package, researchers will find a hard copy of the Certificate of Analysis, which includes HPLC purity, net peptide weight, mass spectrum, and residual solvent data. A materials safety data sheet (MSDS) and a product information sheet with handling instructions are also included. Electronic copies are archived in our customer portal for convenient retrieval during manuscript preparation or grant reporting.
All products listed on this website and sold to customers are intended solely for laboratory research use. They are not designed, labeled, or authorized for use as drugs, food additives, cosmetics, or for any direct human or veterinary application. The purchaser assumes all responsibility for compliance with applicable regulations and for determining the suitability of the product for their specific experimental purposes.
For research use only. Not for human or veterinary use.
